Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of adsorbed acellular DTP component vaccine in infants and young children
ChiCTR2600127620Phase 3Completed
- Sponsor
- Hubei Center for Disease Control and Prevention
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of diphtheria + tetanus + acellular pertussis vaccine in pertussis, diphtheria and Tetanus (3 arms), sponsored by Hubei Center for Disease Control and Prevention. Primary endpoints: Geometric mean concentration (GMC) of antibodies and Antibody positivity rate (seroconversion rate). Started Jul 2026; status: completed.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on ChiCTR2600127620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127620.